Transform UK Pharma Market Insights into Actionable Strategic Plans - Powered by Gain Analytics Ltd.
- Amardeep Nandani
- Oct 25
- 2 min read
At Gain Analytics Ltd., we believe that data-driven insights can redefine growth strategies in the pharmaceutical sector. Leveraging one of the most extensive NHS datasets, we recently explored the UK Pharma Market insightful landscape and uncovered trends shaping the future.
📊 Pharma Market Insights Snapshot
The UK pharma market has reached £29.2 Bn (MAT May 2025), with a steady growth of 5% YoY.
England GP and Secondary Care practices contribute 90%+ of prescription volumes, with Secondary Care driving growth at 9.3% YoY.
📈 Key Trends
Strong momentum observed in Musculoskeletal, Endocrine, and Immunosuppressive therapies, each showing double-digit growth.
Top ICBs like Southeast London and West Yorkshire are fueling regional expansion, while others remain stable.
Molecules like Adalimumab continue to dominate with nearly £1 Bn turnover, while Pembrolizumab (Keytruda) has seen a recent slowdown.
🚀 Movers & Shakers
Mounjaro has scaled rapidly to £23.9 Mn monthly turnover, reshaping the diabetes and weight management segment.
Abiraterone 500mg recorded a sharp price drop (from £48.84 to £18.37 in 3 months), reflecting the pace of generic adoption.
🤝 Why This Matters
For pharma leaders, these insights enable smarter decisions on:
✔ Market entry and expansion
✔ Therapy prioritization
✔ Competitive positioning
✔ Pricing and procurement strategies
🚀 Market Movers
Mounjaro has already crossed £23.9 Mn monthly turnover, reshaping the weight management and diabetes market.
Adalimumab still dominates with close to £1 Bn annual turnover, proving how established biologics sustain long-term leadership.
Pembrolizumab (Keytruda) shows signs of plateauing—an early indicator for competitors to position themselves smartly.
🎯 Strategic Implications
Data is not just information—it’s a decision-making enabler. For leadership teams, these insights can help:
Refine market-entry strategies by focusing on high-growth therapy areas.
Optimize resource allocation across regions and therapy lines.
Build pricing strategies aligned with generic penetration and NHS procurement.
Monitor competitive molecules to anticipate disruptions.
With AI-driven platforms like GainEPD, we help pharma organizations consolidate these insights into interactive dashboards, empowering CXOs to align tactical execution with long-term strategic goals.
🤝 Why Gain Analytics?
Our work is not just about dashboards. It’s about enabling pharma leaders to:
✔ Translate data → insights → action
✔ Align strategies with real-world market shifts
✔ Drive sustainable growth through better foresight
At Gain Analytics LTD, London, UK, we are building solutions that resonate globally. Our expertise is helping clients unlock new opportunities, reduce risks, and execute with clarity.
Have glimpses here:
At Gain Analytics, our AI-driven GainEPD platform integrates NHS data, advanced analytics, and visualizations on Power BI—helping clients unlock opportunities, manage risks, and scale sustainably.
✨ We’re proud to support the pharma ecosystem with actionable insights. If you’re keen to explore the UK Pharma market, we’d be happy to walk you through how Gain Analytics can partner in your growth story.
Comments